FY2025 EPS Estimates for Personalis Boosted by HC Wainwright

Personalis, Inc. (NASDAQ:PSNL) – Research analysts at HC Wainwright raised their FY2025 EPS estimates for shares of Personalis in a note issued to investors on Thursday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.92) for the year, up from their prior forecast of ($1.00). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Personalis’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Personalis’ Q4 2025 earnings at ($0.27) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at ($0.56) EPS and FY2029 earnings at $0.02 EPS.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The business had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.31 million. Personalis has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS.

PSNL has been the subject of several other reports. BTIG Research lifted their price target on Personalis from $6.00 to $11.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Needham & Company LLC raised their price objective on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday. Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, September 20th. Lake Street Capital reissued a “buy” rating and issued a $11.00 target price on shares of Personalis in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.33.

Personalis Price Performance

Shares of NASDAQ PSNL opened at $6.93 on Monday. Personalis has a one year low of $2.83 and a one year high of $10.95. The business’s 50-day moving average price is $7.33 and its two-hundred day moving average price is $6.09. The company has a market capitalization of $615.38 million, a P/E ratio of -7.88 and a beta of 1.92.

Hedge Funds Weigh In On Personalis

Institutional investors and hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. boosted its holdings in Personalis by 33.9% in the 1st quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after purchasing an additional 17,056 shares during the period. Trexquant Investment LP raised its position in shares of Personalis by 455.0% during the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock valued at $432,000 after buying an additional 100,804 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after buying an additional 101,706 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its position in Personalis by 67.0% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 92,841 shares of the company’s stock worth $609,000 after buying an additional 37,258 shares in the last quarter. Finally, XTX Topco Ltd grew its position in Personalis by 147.0% during the first quarter. XTX Topco Ltd now owns 82,666 shares of the company’s stock worth $290,000 after buying an additional 49,197 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

Insider Buying and Selling

In other news, CEO Christopher M. Hall sold 29,612 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the transaction, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. The trade was a 16.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.